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Position Statement
tion.com.au). The process of guideline developmen
ised in Box 1 and the grades of recommendation a
Box 2.
Background
Acute rheumatic fever (ARF) is an autoimmune coMJA • Volume 186 NumABSTRACT
• Acute rheumatic fever (ARF) and rheumatic heart disease (RHD) 
are diseases of poverty. They occur at world-record rates in 
Indigenous Australians, yet individual cases are often poorly 
managed, and most jurisdictions with high rates of these 
diseases do not have formal control strategies in place.
• New Australian guidelines formulated in 2005 by the National 
Heart Foundation of Australia and the Cardiac Society of 
Australia and New Zealand for diagnosis and management of 
ARF and RHD are a valuable resource for clinicians and 
policymakers.
• Key recommendations of the guidelines include:
? New diagnostic criteria for ARF in high-risk populations, 
including Indigenous Australians, which include 
echocardiographic evidence of subclinical valvular disease, and 
polyarthralgia or aseptic monoarthritis as major manifestations.
? Clear guidance about treatment of ARF. Non-steroidal anti-
inflammatory drugs should be withheld until the diagnosis is 
confirmed, and corticosteroids may be an option in severe acute 
carditis. Most cases of chorea do not require medication, but use 
of carbamazepine or sodium valproate is recommended if 
medication is needed.
? Clear guidance about dose, dosing frequency and duration 
of secondary prophylaxis. Benzathine penicillin G is the 
preferred medication for this purpose.
? Establishment of a coordinated control program for all 
regions of Australia where there are populations with high 
prevalence of ARF and RHD. Key elements and indicators for 
evaluation are recommended.
? Active screening and legislated notification of ARF and RHD, 
where possible.
? Development of a structured care plan for all patients with a 
history of ARF or with established RHD, to be recorded in the 
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patient’s primary health care record.
For editorial comment, see page 557he
Ca
recT  National Heart Foundation of Australia (NHFA) and therdiac Society of Australia and New Zealand (CSANZ)ently launched an evidence-based review and guideline
entitled Diagnosis and management of acute rheumatic fever and
rheumatic heart disease in Australia.1 The full review and guideline,
along with five quick reference guides for professionals, are




infection with group A streptococci (GAS). It causes an acute
generalised inflammatory response and an illness that selectively
affects the heart, joints, brain and skin. People with ARF are often
severely unwell and in great pain, and require hospitalisation.
Despite the dramatic nature of an acute episode, ARF leaves no
lasting damage to the brain, joints or skin.
However, damage to the heart valves, particularly the mitral and
aortic valves, may persist after an acute episode has resolved. This
involvement of the cardiac valves is known as rheumatic heart
disease (RHD). People who have had ARF previously are much
more likely to have subsequent episodes, and these recurrences
may cause further damage to the cardiac valves. Thus RHD steadily
worsens in people who have multiple episodes of ARF.4
A recent review of the global burden of GAS-related disease
estimated that there are at least 15.6 million people with RHD,
another 1.9 million with a history of ARF but no carditis (still
requiring preventive treatment), 470 000 new cases of ARF each
year, and over 230 000 deaths due to RHD annually.5 Almost all
cases and deaths occur in developing countries. Because of its high
prevalence in developing countries, RHD is the most common
form of paediatric heart disease in the world. In many countries it
is the most common cause of cardiac mortality in children and
adults aged less than 40 years.
Currently, the highest documented rates of ARF and RHD in the
world are in Indigenous Australians. A recent summary of the data
on the disease burden of ARF and RHD in Australia concluded that
these diseases are almost exclusively restricted to Aboriginal and
Torres Strait Islander people living in regional and remote areas of
central and northern Australia.6 The annual incidence of ARF in
Aboriginal children aged 5–14 years in the Northern Territory
ranged from 250 to 350 per 100 000. Enhanced surveillance in
northern Queensland between 1999 and 2004 found an annual
incidence of ARF in Aboriginal children aged 5–14 years of 162
per 100 000.7
In the NT in 2002, the prevalence of RHD was 13–17 cases per
1000 Aboriginal people of all ages, compared with less than two
* Other members of the Writing Group were Warren Walsh, Clive Hadfield, 
Diana Lennon, Lynette Purton and Gavin Wheaton.
1 Guideline development process
1. Expert writing group prepared an initial draft.
2. Thirty-seven selected individuals reviewed the draft chapters, and 
their suggestions were incorporated into a second draft.
3. The revised draft was widely circulated to 17 stakeholder 
organisations for comment, and stakeholders were also invited to a 
1-day workshop in November 2004.
4. At the workshop, the stakeholders reviewed the draft and reached 
a consensus on areas of disagreement.
5. A third draft was prepared and redistributed to stakeholder 
organisations for further comment.
6. The final draft was then prepared and endorsed by 10 stakeholder 
organisations as well as the National Heart Foundation of Australia 
and the Cardiac Society of Australia and New Zealand. ◆ber 11 • 4 June 2007 581
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Indigenous people are up to eight times more likely than non-
Indigenous Australians to be hospitalised for ARF and RHD, and
nearly 20 times as likely to die. Forty-five per cent of Indigenous
people receiving heart valve surgery for RHD are aged less than 25
years, compared with only 4% of non-Indigenous Australians.
Several factors contribute to inadequate diagnosis and manage-
ment of ARF and RHD in Australia:
• Although strategies for preventing RHD are proven, simple,
cheap and cost-effective, they are not adequately implemented —
indeed, they are sometimes not implemented at all in the popula-
tions at highest risk of the disease;
• As ARF is rare in most metropolitan centres where health
professionals train and practise, the majority of clinicians will have
seen very few, if any, cases of ARF;
• There is great variability in the management of ARF and RHD.
Lack of up-to-date training and experience occasionally results in
inappropriate management of these diseases; and
• Population groups who experience the highest rates of ARF and
RHD have limited access to health care services.
The guidelines do not cover primordial or primary preven-
tion in detail. This is because the key to primordial prevention
is reducing exposure to GAS, which requires dramatic improve-
ments in housing, hygiene infrastructure and access to health
care for Indigenous Australians. Beyond these reforms, there are
no systematic approaches that are proven to reduce the inci-
dence of ARF. It should be noted that penicillin treatment of
streptococcal pharyngitis (primary prophylaxis) has been
proven to reduce the occurrence of subsequent episodes of
ARF,8 and this should continue to be emphasised to health staff.
However, systematic screening and treatment of sore throats —
for example, in school-based programs — has not been proven
to be cost-effective.9
2 Grades of recommendation and levels of evidence*
Grade Level of evidence
A Rich body of high-quality RCT data
B Limited body of RCT data or high-quality non-RCT data
C Limited evidence
D No evidence available — panel consensus judgement
RCT = randomised controlled trial. * Levels of evidence and grades of 
recommendation are adapted from National Health and Medical Research 
Council levels of evidence for clinical interventions2 and US National Institutes 
of Health clinical guidelines.3 ◆582 MJA • Volume 186 Number 11 • 4 June 2007
3 2005 Australian guidelines for the diagnosis of acute rheumatic fever (ARF)*
High-risk groups† All other groups
Initial episode of ARF 2 major OR 1 major and 2 minor manifestations, PLUS evidence 
of a preceding group A streptococcal infection‡
As for high-risk groups
Recurrent attack of ARF in a patient 
with known past ARF or RHD
2 major OR 1 major and 2 minor OR 3 minor manifestations, 
PLUS evidence of a preceding group A streptococcal infection‡
As for high-risk groups
Major manifestations Carditis (including subclinical evidence of rheumatic 
valvular disease on echocardiogram)




Carditis (excluding subclinical evidence of 






ESR 30 mm/h or CRP level 30 mg/L
Prolonged PR interval on ECG‡‡
Fever††
ESR  30mm/h or CRP level  30mg/L
Prolonged PR interval on ECG‡‡
Polyarthralgia or aseptic monoarthritis§
CRP = C-reactive protein. ECG = electrocardiogram. ESR = erythrocyte sedimentation rate. RHD = rheumatic heart disease.
*All categories assume that other more likely diagnoses have been excluded. Patients who do not fulfil the criteria listed here, but for whom the clinician remains suspicious that 
the diagnosis may be ARF, should be offered a single dose of benzathine penicillin G at secondary prophylaxis doses and reviewed in 1 month with a repeat echocardiogram to 
detect the appearance of new lesions. If there is evidence of rheumatic valvular disease, clinically or on echocardiogram, the diagnosis is confirmed, and long-term secondary 
prophylaxis can be continued. See text for details about specific manifestations.
† High-risk groups are those living in communities with high rates of ARF (incidence >30 per 100000 per year in 5–14-year-olds) or RHD (all-age prevalence >2 per 1000). 
Indigenous Australians living in rural or remote settings are known to be at high risk. Data are not available for other populations, but Indigenous Australians living in urban 
settings, Ma¯ori and Pacific Islander people, and, potentially, immigrants from developing countries may also be at high risk.
‡ Elevated or rising level of antistreptolysin O or other streptococcal antibody; positive throat swab culture; or positive rapid antigen test for group A streptococci.
§ A definite history of arthritis is sufficient to satisfy this manifestation. Other causes of arthritis or arthralgia should be excluded, particularly in the case of monoarthritis (eg, septic 
arthritis due to disseminated gonococcal infection); infective or reactive arthritis (eg, due to Ross River virus, Barmah Forest virus, influenza virus, rubella virus, Mycoplasma, 
cytomegalovirus, Epstein–Barr virus, parvovirus, hepatitis or Yersinia); autoimmune arthropathy (eg, associated with juvenile chronic arthritis, inflammatory bowel disease, 
systemic lupus erythematosus, systemic vasculitis or sarcoidosis). If polyarthritis is present as a major manifestation, polyarthralgia or aseptic monoarthritis cannot be considered 
an additional minor manifestation in the same person.
¶Rheumatic (Sydenham’s) chorea does not require other manifestations or evidence of preceding group A streptococcal infection, provided other causes of chorea are excluded.
**Erythema marginatum is a distinctive rash. Care should be taken not to label other rashes, particularly non-specific viral exanthems, as erythema marginatum.
††Oral, tympanic or rectal temperature 38°C on admission or documented during the current illness.
‡‡If carditis is present as a major manifestation, prolonged PR interval cannot be considered an additional minor manifestation in the same person. ◆
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The Jones criteria for diagnosing ARF divide its clinical features
into major and minor manifestations.10 There is some concern that
these criteria may not be sensitive enough in high-incidence
populations, where the consequences of under-diagnosis may be
greater than those of over-diagnosis. An expert group convened by
the World Health Organization in 2001 provided additional
guidelines on how the Jones criteria should be applied in primary
and recurrent episodes.4 Because the Jones and WHO criteria
appear too restrictive for diagnosing ARF in Australian Indigenous
populations, the NHFA and CSANZ have agreed on new criteria
for use in high- and low-risk populations in Australia (Box 3). In
high-risk populations, echocardiographic evidence of subclinical
valvular disease and polyarthralgia or aseptic monoarthritis can be
considered major manifestations of ARF. All patients with possible
or confirmed ARF should undergo echocardiography to help in
making the diagnosis and to determine the level of cardiac
involvement (grade C recommendation).
Other investigations recommended in suspected ARF cases
include biochemical testing (for levels of inflammatory markers),
blood culture (if the patient is febrile), an electrocardiogram (to
detect a prolonged PR interval), a chest x-ray (if there is evidence
of carditis), a throat swab (for culture of GAS), and streptococcal
serology (both antistreptolysin O and anti-DNase B titres). In
seeking alternative diagnoses, investigations may include repeat
blood cultures for possible endocarditis; joint fluid culture for
possible septic arthritis; levels of copper, ceruloplasmin, antinuc-
lear antibody and drugs for other causes of abnormal movements;
and serology and autoimmune markers for arboviral, autoimmune
or reactive arthritis.
Two recently described putative syndromes associated with
infection with GAS are post-streptococcal reactive arthritis and
paediatric autoimmune neuropsychiatric disorders associated with
streptococcal infections. However, because of difficulties in differ-
entiating them from ARF, these conditions should rarely, if ever, be
diagnosed in high-risk populations such as Indigenous Australians
(grade C recommendation).
Treatment of acute rheumatic fever
The priorities in managing ARF are listed in Box 4. With very few
exceptions, all patients with definite or possible ARF should be
admitted to hospital (grade D recommendation). The arthritis of
ARF is exquisitely responsive to treatment with non-steroidal anti-
inflammatory drugs (NSAIDs). Indeed, this can be a useful
diagnostic feature, as arthritis continuing unabated more than 3
days after starting NSAID therapy is unlikely to be due to ARF.
Equally, withholding NSAIDs in patients with monoarthralgia or
mono-arthritis to observe the development of polyarthritis can
help confirm the diagnosis of ARF. Therefore, salicylates or NSAIDs
should be withheld until the diagnosis is confirmed. Joint pain can
be treated with paracetamol (grade D recommendation). Most
cases of chorea can be managed without medication. Where
necessary — because of severe movement disorder or distress —
treatment with carbamazepine or valproic acid is recommended
(grade B recommendation). Treatment with corticosteroids has not
been proven to alter the likelihood of developing RHD or its
degree of severity.11 However, this statement is not based on high-
quality evidence, and there are no published trials of the possible
shorter-term benefits of corticosteroids in severe carditis, the
condition for which they are usually reserved. Therefore, the use of
these medications is optional, but if used, they should be reserved
for severe carditis only (grade D recommendation).
Secondary prevention
Regular administration of antibiotics to prevent infection with GAS
and subsequent possible recurrent ARF is recommended for all
people with a history of ARF or RHD (grade A recommendation).
This strategy has been proven in randomised controlled trials to
4 Priorities in managing acute rheumatic fever (ARF)
Admission to hospital
Confirmation of diagnosis
Observation before anti-inflammatory treatment (paracetamol 
[first-line] or codeine for fever or joint pain)




Single dose intramuscular benzathine penicillin G (preferable) or 
oral penicillin V for 10 days (intravenous penicillin not needed; 
oral erythromycin may be used if patient allergic to penicillin)
Arthritis and fever
Paracetamol (first-line) or codeine until diagnosis confirmed
Aspirin (first-line) or naproxen once diagnosis confirmed, if 
arthritis or severe arthralgia present
Mild arthralgia and fever may respond to paracetamol alone
Influenza vaccine for children receiving aspirin during the 
influenza season (autumn/winter)
Chorea
No treatment for most cases
Carbamazepine or valproic acid if treatment is necessary (see 





• Diuretics/fluid restriction for mild to moderate heart failure
• ACE inhibitors for more severe heart failure, particularly if 
aortic regurgitation present
• Glucocorticoids optional for severe carditis (consider 
treating for possible opportunistic infections)
• Digoxin if atrial fibrillation present
Valve surgery for life-threatening acute carditis (rare)
Long-term preventive measures
Give first dose of secondary prophylaxis
Notify case for recording in ARF/RHD register, if available
Contact local health staff to ensure follow-up
Provide culturally appropriate education to patient and family
Arrange dental review and ongoing dental care to reduce risk of 
endocarditis
ACE = angiotensin-converting enzyme. RHD = rheumatic heart disease. ◆MJA • Volume 186 Number 11 • 4 June 2007 583
POSITIO N STATEMENTprevent streptococcal pharyngitis and recurrent ARF and to reduce
the severity of and mortality from RHD. Intramuscular benzathine
penicillin G (BPG) is superior to oral penicillin.12 Dosing regimens
are shown in Box 5. A lower dose for children weighing < 20 kg has
been shown in New Zealand to maintain low ARF recurrence rates,
although the number of children receiving this regimen was small.13
BPG is most effectively given as a deep intramuscular injection into
the upper outer quadrant of the buttock or the anterolateral thigh.
Three-weekly delivery of BPG has been shown to be more
effective than 4-weekly delivery in some studies.12,14-16 Although
Australian Indigenous people are at higher risk of developing ARF
than other ethnic groups in Australia, the benefits of 3-weekly BPG
injections for Indigenous Australians in remote areas are offset by
the difficulty of achieving good treatment adherence, even to the
standard 4-weekly regimen. Moreover, prospective data from New
Zealand have shown that there are few, if any, recurrences of ARF
among people who adhere to a strict 4-weekly BPG regimen.13 Thus
the use of 4-weekly BPG is currently the treatment of choice, except
in patients with moderate to severe carditis or a history of valve
surgery who show good adherence to less frequent injections, and
those who have confirmed breakthrough ARF despite full adherence
to a 4-weekly BPG regimen, in whom 3-weekly administration is
recommended (grade D recommendation). Monthly rather than 4-
weekly administration of BPG is an acceptable alternative only if it is
considered that the practicalities of monthly dosing will substan-
tially improve adherence (grade D recommendation).
Oral penicillin is less effective than BPG in preventing group A
streptococcal infections and subsequent recurrences of ARF. More-
over, in comparison with intramuscular BPG, twice-daily oral regi-
mens are likely to result in poorer rates of adherence over long time
periods and less predictable serum penicillin concentrations. Oral
penicillin should be reserved for patients who refuse intramuscular
BPG (grade B recommendation). If a patient is offered oral penicillin,
the consequences of missed doses must be emphasised, and adher-
ence needs to be carefully monitored (grade D recommendation).
Before commencing penicillin treatment, patients should be care-
fully questioned about known allergies to penicillin or other β-
lactam antibiotics. If there is substantive evidence of immediate and
severe allergic reaction to penicillin, a non-β-lactam antimicrobial
(eg, erythromycin) should be used instead (grade D recommenda-
tion). If patients state they are allergic to penicillin but there is no
unequivocal evidence of a previous allergic reaction, they should be
investigated for penicillin allergy, preferably in consultation with an
allergist. Penicillin desensitisation is not applicable to these patients,
as it would have to be repeated before each dose of BPG.
As there is no evidence of teratogenicity associated with it,
penicillin prophylaxis for prevention of recurrent ARF should con-
tinue for the duration of pregnancy (grade D recommendation).
Erythromycin is also considered safe for use in pregnancy, although
controlled trials have not been conducted. Intramuscular bleeding
from BPG injections, used in conjunction with anticoagulation
therapy in Australia, is rare. Thus, BPG injections should be contin-
ued for patients receiving an anticoagulant, unless there is evidence
of uncontrolled bleeding or the international normalised ratio is
above the defined therapeutic range (grade D recommendation).
The appropriate duration of secondary prophylaxis is deter-
mined by age, time since the last episode of ARF, and potential
harm from recurrent ARF (Box 6) (grade D recommendation).
Poor adherence to treatment is rarely due to injection refusal, the
pain of injections, or a lack of knowledge or understanding of ARF/
RHD in remote Indigenous communities.17 The major determining
factors are the availability and acceptability of health services and the
presence of active reminder and recall systems. Adherence is
substantially better in health centres where there is active follow-up
if BPG doses are missed and where a dedicated staff member
administers the BPG (AB, unpublished data).
Infective endocarditis is a dangerous complication of RHD and a
common adverse event after prosthetic valve replacement in Indige-
nous Australians.18 People with established RHD or prosthetic
valves should receive antibiotic prophylaxis before undergoing
5 Recommended antibiotic regimens and their duration for secondary prevention of acute rheumatic fever (ARF) and 
rheumatic heart disease (RHD)
Antibiotic Dose Route Frequency Duration
First-line treatment
Benzathine penicillin G 
(BPG)
1 200 000 U (body 




4-weekly, or 3-weekly 
for selected groups*
All people with ARF or RHD:
• Minimum 10 years after most recent episode of 
ARF or until age 21 years (whichever is longer)
600 000 U (body 
weight < 20 kg)
Second-line treatment (if intramuscular routine not possible or refused)† Status after initial period has elapsed:‡
• No RHD or mild RHD: discontinue at that time
• Moderate RHD: continue until age 35 years




250 mg Oral Twice daily
Treatment in cases of documented penicillin allergy
Erythromycin 250 mg Oral Twice daily
* 3-weekly BPG injections may be considered for patients with moderate to severe carditis or a history of valve surgery who demonstrate good adherence to less frequent 
injections and for those who have confirmed breakthrough ARF despite full adherence to 4-weekly BPG treatment. Monthly BPG injections are an acceptable alternative 
only if it is considered that the practicalities of monthly dosing will substantially improve adherence.
† If oral regimens are prescribed, adherence should be carefully monitored.
‡ Decisions to cease secondary prophylaxis should be based on clinical and echocardiographic assessment. See full guideline for definitions of RHD severity.
§ Risk of recurrence is extremely low in people aged > 40 years. In some cases (eg, if a patient wants to reduce even a minimal risk of recurrence), prophylaxis may be 
continued beyond age 40 years, or even for life. ◆584 MJA • Volume 186 Number 11 • 4 June 2007
POSITIO N STATEMENTprocedures expected to produce bacteraemia. Individuals with a
history of ARF but no valvular damage do not require antibiotic
prophylaxis. Those already receiving penicillin for secondary pro-
phylaxis should be offered a different antibiotic for prophylaxis of
endocarditis. Recommendations are outlined in the full guideline.
Rheumatic heart disease control programs
A coordinated control program is the most effective approach for
improving BPG adherence and clinical follow-up of people with
RHD.4,13,19 The other aims of control programs are to identify and
register new cases of ARF and RHD; to provide education and
training for health care providers; to provide education and health
promotion for individuals, families and the community; to pro-
mote primary prevention of ARF; and to monitor patient outcomes
and improve program strategies.
Maintaining registers of people with RHD or a history of ARF is
a key element of RHD control at individual, community and
national levels. Register-based programs improve case detection,
increase adherence to secondary prophylaxis, reduce recurrences
of ARF, and reduce hospitalisations for ARF and RHD. Registers
also provide a mechanism for monitoring patient movements,
6 Recommended routine review and management plan for acute rheumatic fever (ARF) and rheumatic heart disease (RHD)
Classification Criteria* Review and management plan Frequency†
Low risk ARF with no evidence of RHD
OR
Trivial to mild valvular disease





• Children 2-yearly;‡ adults 2–3-yearly‡
Medium risk Any moderate valve lesion in 
the absence of symptoms and 











• Polysaccharide pneumococcal vaccination 









• 5-yearly (maximum 3 doses)
• As required
High risk§ Severe valvular disease
OR
Moderate to severe valvular 
lesion with symptoms
OR
Tissue prosthetic valves and 
valve repairs






• Polysaccharide pneumococcal vaccination 
(Pneumovax 23 [Merck Sharp & Dohme])
• Endocarditis prophylaxis






• Within 3 months and yearly thereafter









• Full blood count
• Levels of urea, creatinine, electrolytes
• INR if indicated
• 3–4 weeks after discharge
Missed doses of BPG • Patient should be contacted if he or she has not 
presented within 3 days of due injection
Patient travelling to another 
community when injection 
due
• Consider bringing forward date of injection to 2–3 
weeks, or make arrangements with other service 
providers in advance
BPG = benzathine penicillin G. ECG = electrocardiogram. INR = international normalised ratio.
* Serial echocardiographic assessments are required for long-term management of RHD. If cultural differences or difficulties with communication hinder standard clinical 
measures of heart failure (eg, New York Heart Association criteria), serial echocardiography becomes an essential tool for determining the progress of cardiac damage 
and optimal timing of surgery. Thus, risk stratification should be based on clinical and echocardiographic findings.
† Frequency of review should be determined according to individual needs and local capacity. Most critically, review should become more frequent in the event of 
symptom onset, symptomatic deterioration, or a change in clinical findings.
‡ In patients with no evidence of valvular disease on echocardiography, no documented ARF recurrences, good adherence to secondary prophylaxis, and no cardiac 
murmurs on examination at follow-up appointments, echocardiography may be needed less frequently.
§ Any patient with severe valvular disease or moderate to severe valvular disease with symptoms should be referred for cardiological and surgical assessment as soon 
as possible. ◆MJA • Volume 186 Number 11 • 4 June 2007 585
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clinic appointments and echocardiograms), and identifying indi-
viduals with poor adherence to long-term therapy for targeted
educational activities and other interventions. Registers can also
provide data for monitoring the success of programs and changes
in disease epidemiology. It is recommended that all regions of
Australia in which there are substantial numbers of people with
ARF or RHD establish a coordinated control program (see full
guideline for recommended elements of programs) (grade C
recommendation).
A dedicated coordinator is critical to the success of the program.
This person should have skills in data management, basic epidemi-
ology and clinical medicine, or ready access to clinical expertise
when individual case management issues arise. Ideally, active
surveillance of ARF and RHD should be used to augment passive
surveillance. Active surveillance could include mechanisms allow-
ing access to hospital separation data, echocardiography reports,
specialist review correspondence, primary health care clinic infor-
mation, and notifiable disease databases. Where possible, these
processes should be automated (eg, with regular downloads of
information about patients admitted to hospital with a diagnosis of
ARF or RHD). Active screening and legislated notification of ARF
and RHD should be considered where possible (grade D recom-
mendation). Proposed indicators for evaluating programs are
outlined in the full guideline.
Management of rheumatic heart disease
A structured care plan should be developed and recorded in the
primary health care record of all people with a history of ARF or
with established RHD (grade D recommendation). The recom-
mended care plan schedules listed in Box 6 may be tailored to the
needs of the individual. Medical and surgical management of
rheumatic valvular lesions is reviewed in the full guideline, and
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